Teleflex raises earnings forecast despite flat sales, as portfolio overhaul continues

Teleflex is giving shareholders a higher profit target even though its top line barely moved. Revenue from continuing operations for the three months to 30 September came in at $567.8m, up 0.2% on a reported basis. Measured on a pro forma, adjusted, constant-currency basis, growth was 3.0%.

On that footing, management now expects 2026 adjusted earnings per share of $7.50 to $7.75. The company did not change its constant-currency growth outlook, so the revised guidance applies to earnings rather than to sales expectations.

Capital return and restructuring were prominent in the update. Teleflex said it has bought back $350m of its own shares since 1 July. It has also completed the divestiture of its OEM business. A separate agreement to sell its Acute Care and Interventional Urology businesses to Intersurgical is still pending and depends on regulatory approval, so those units remain with Teleflex for now.

In pipeline news, the US Food and Drug Administration has granted Breakthrough Device Designation to Freesolve, Teleflex's magnesium scaffold for percutaneous coronary intervention (PCI). The designation is meant to speed the review of devices aimed at serious conditions. It is not marketing authorisation, and the company's statement does not set out a timetable for approval or launch.